Gemina Laboratories Ltd.
GLABF · OTC
1/31/2025 | 1/31/2024 | 1/31/2023 | 1/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $2 | $4 | $3 |
| G&A Expenses | $0 | $2 | $2 | $2 |
| SG&A Expenses | $3 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $4 | $5 | $6 | $5 |
| Operating Income | -$4 | -$5 | -$6 | -$5 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$4 | -$5 | -$6 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$5 | -$6 | -$5 |
| % Margin | – | – | – | – |
| EPS | -0.055 | -0.072 | -0.099 | -0.099 |
| % Growth | 23.6% | 27.5% | 0.1% | – |
| EPS Diluted | -0.055 | -0.072 | -0.099 | -0.099 |
| Weighted Avg Shares Out | 74 | 72 | 60 | 48 |
| Weighted Avg Shares Out Dil | 74 | 72 | 60 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$5 | -$6 | -$5 |
| % Margin | – | – | – | – |